Neurotech International (ASX:NTI) ROE % Adjusted to Book Value : -2.41% (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Neurotech International ROE % Adjusted to Book Value?

Neurotech International's ROE % for the quarter that ended in Dec. 2023 was -33.30%. Neurotech International's PB Ratio for the quarter that ended in Dec. 2023 was 13.80. Neurotech International's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was -2.41%.

Neurotech International ROE % Adjusted to Book Value Historical Data

The historical data trend for Neurotech International's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurotech International ROE % Adjusted to Book Value Chart

Neurotech International Annual Data

Trend

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-21.21

-52.35

-3.63

-36.13

Neurotech International Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROE % Adjusted to Book Value	Get a 7-Day Free Trial										-7.18	-4.12	-20.55	-17.00	-2.41

Competitive Comparison of Neurotech International's ROE % Adjusted to Book Value

For the Medical Devices subindustry, Neurotech International's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neurotech International's ROE % Adjusted to Book Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Neurotech International's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Neurotech International's ROE % Adjusted to Book Value falls into.

Neurotech International ROE % Adjusted to Book Value Calculation

Neurotech International's ROE % Adjusted to Book Value for the fiscal year that ended in Jun. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-289.02%	/	8.00
	=	-36.13%

Neurotech International's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-33.30%	/	13.80
	=	-2.41%

Neurotech International ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Neurotech International's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Neurotech International (ASX:NTI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Neurotech International Ltd (ASX:NTI) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

145 Stirling Highway, Suite 5 CPC, Nedlands, WA, AUS, 6009

Website

https://www.neurotechinternational.com

Neurotech International Ltd is a medical device and solutions company. It researches, designs, markets, and produces wearable neurotechnology devices to assist with neurological conditions such as autism. Geographically, all the business activities of the firm function through the region of Australia. It operates in one segment named Medical Device Development and Distribution.

Neurotech International (ASX:NTI) Headlines

From GuruFocus

How to Capitalize on the Bakken Oil Boom

By Vitaliy Katsenelson Vitaliy Katsenelson • 11-09-2013

By Dividend Dividend • 06-25-2013

9 Stocks With Yields Over 10% And Buy Or Better Rating

By Dividend Dividend • 08-17-2013

18 Stocks with Very High Yields (More Than 10%) and Earnings Growth

By Dividend Dividend • 12-20-2012

9 Stocks with Double-Digit Yields and Buy or Better Recommendations

By Dividend Dividend • 07-17-2013

20 Stocks with Yields over 10% and Highest Buy Ratings

By Dividend Dividend • 01-17-2013

13 Stocks With Dividend Yields Over 10%

By Dividend Dividend • 11-12-2014